A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors

Abstract

Rapid advances in synthetic biology are driving the development of microbes as therapeutic agents. While the immunosuppressive tumor microenvironment creates a favorable niche for the systematic delivery of bacteria and therapeutic payloads, these can be harmful if released into healthy tissues. To address this limitation, we designed a spatiotemporal targeting system for engineered Escherichia coli Nissle 1917, controlled by azide-modified hyaluronic acid hydrogel and near-infrared radiation induction. Using a temperature-driven genetic status switch, the system produced durable therapeutic output and promoted the therapeutic activity in solid tumors. The combination of azide-modified hyaluronic acid hydrogel and temperature-sensitive, engineered Escherichia coli Nissle 1917 provided spatiotemporal targeting of solid tumors, not only showing significant therapeutic effects on primary solid tumors, but also inhibiting the metastasis and recurrence of cancer cells by enhancing tumor-infiltrating lymphocytes. This system has potential for clinical application.

Keywords

bioengineered hydrogels / long-term antitumor protection / spatiotemporal localization of therapeutic bacteria

References

[1] A. J. Hou, L. C. Chen, and Y. Y. Chen, “Navigating CAR-T Cells Through the Solid-tumour Microenvironment,” Nature Reviews Drug Discovery20 (2021): 531-550, https://doi.org/10.1038/s41573-021-00189-2.

[2] J. Tang, V. M. Hubbard-Lucey, L. Pearce, J. O'Donnell-Tormey, and A. Shalabi, “The Global Landscape of Cancer Cell Therapy,” Nature Reviews Drug Discovery17 (2018): 465-466, https://doi.org/10.1038/nrd.2018.74.

[3] N. Kanaya, Y. Kitamura, M. Lopez Vazquez, et al., “Gene-Edited and -Engineered Stem Cell Platform Drives Immunotherapy for Brain Metastatic Melanomas,” Science Translational Medicine15 (2023): eade8732, https://doi.org/10.1126/scitranslmed.ade8732.

[4] L. Ma, A. Hostetler, D. M. Morgan, et al., “Vaccine-Boosted CAR T Crosstalk With Host Immunity to Reject Tumors With Antigen Heterogeneity,” Cell186 (2023): 3148-3165.e20, https://doi.org/10.1016/j.cell.2023.06.002.

[5] M. P. McNerney, K. E. Doiron, T. L. Ng, T. Z. Chang, and P. A. Silver, “Theranostic Cells: Emerging Clinical Applications of Synthetic Biology,” Nature Reviews Genetics22 (2021): 730-746, https://doi.org/10.1038/s41576-021-00383-3.

[6] M. Hong, J. D. Clubb, and Y. Y. Chen, “Engineering CAR-T Cells for Next-Generation Cancer Therapy,” Cancer Cell38 (2020): 473-488, https://doi.org/10.1016/j.ccell.2020.07.005.

[7] J. Yang, Y. Chen, Y. Jing, M. R. Green, and L. Han, “Advancing CAR T Cell Therapy Through the Use of Multidimensional Omics Data,” Nature Reviews Clinical Oncology20 (2023): 211-228, https://doi.org/10.1038/s41571-023-00729-2.

[8] D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson, et al., “T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-escalation Trial,” The Lancet385 (2015): 517-528, https://doi.org/10.1016/S0140-6736(14)61403-3.

[9] N. Wellhausen, R. P. O'Connell, S. Lesch, et al., “Epitope Base Editing CD45 in Hematopoietic Cells Enables Universal Blood Cancer Immune Therapy,” Science Translational Medicine15 (2023): eadi1145.

[10] G. Casirati, A. Cosentino, A. Mucci, et al., “Epitope Editing Enables Targeted Immunotherapy of Acute Myeloid Leukaemia,” Nature621 (2023): 404-414, https://doi.org/10.1038/s41586-023-06496-5.

[11] K. E. de Visser and J. A. Joyce, “The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth,” Cancer Cell41 (2023): 374-403, https://doi.org/10.1016/j.ccell.2023.02.016.

[12] W. Zou, “Immunosuppressive Networks in the Tumour Environment and Their Therapeutic Relevance,” Nature Reviews Cancer5 (2005): 263-274, https://doi.org/10.1038/nrc1586.

[13] D. J. Irvine, M. V. Maus, D. J. Mooney, and W. W. Wong, “The Future of Engineered Immune Cell Therapies,” Science378 (2022): 853-858, https://doi.org/10.1126/science.abq6990.

[14] S. Rafiq, C. S. Hackett, and R. J. Brentjens, “Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy,” Nature Reviews Clinical Oncology17 (2020): 147-167, https://doi.org/10.1038/s41571-019-0297-y.

[15] G. D. Sepich-Poore, L. Zitvogel, R. Straussman, J. Hasty, J. A. Wargo, and R. Knight, “The Microbiome and Human Cancer,” Science371 (2021): eabc4552, https://doi.org/10.1126/science.abc4552.

[16] D. Nejman, I. Livyatan, G. Fuks, et al., “The Human Tumor Microbiome Is Composed of Tumor Type–Specific Intracellular Bacteria,” Science368 (2020): 973-980, https://doi.org/10.1126/science.aay9189.

[17] N. Iida, A. Dzutsev, C. A. Stewart, et al., “Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment,” Science342 (2013): 967-970, https://doi.org/10.1126/science.1240527.

[18] B. A. Helmink, M. A. W. Khan, A. Hermann, V. Gopalakrishnan, and J. A. Wargo, “The Microbiome, Cancer, and Cancer Therapy,” Nature Medicine25 (2019): 377-388, https://doi.org/10.1038/s41591-019-0377-7.

[19] C. R. Gurbatri, N. Arpaia, and T. Danino, “Engineering Bacteria as Interactive Cancer Therapies,” Science378 (2022): 858-864, https://doi.org/10.1126/science.add9667.

[20] M. O. Din, T. Danino, A. Prindle, et al., “Synchronized Cycles of Bacterial Lysis for In Vivo Delivery,” Nature536 (2016): 81-85, https://doi.org/10.1038/nature18930.

[21] L. G. Bermúdez-Humarán, “Lactococcus Lactis as a Live Vector for Mucosal Delivery of Therapeutic Proteins,” Human Vaccines5 (2009): 264-267, https://doi.org/10.4161/hv.5.4.7553.

[22] J. Vockley, N. Sondheimer, M. Puurunen, et al., “Efficacy and Safety of a Synthetic Biotic for Treatment of Phenylketonuria: A Phase 2 Clinical Trial,” Nature Metabolism5 (2023): 1685-1690, https://doi.org/10.1038/s42255-023-00897-6.

[23] G. Argentino and S. Borrelli, “Prevention of Recurrence of Enteric Peritonitis in Peritoneal Dialysis With Escherichia coli Nissle 1917: A Case-Series Study,” Clinical Nephrology96 (2021): 17-21, https://doi.org/10.5414/CN110271.

[24] M. Schultz, “Clinical Use of E. coli Nissle 1917 in Inflammatory Bowel Disease,” Inflammatory Bowel Diseases14 (2008): 1012-1018, https://doi.org/10.1002/ibd.20377.

[25] M. Li, N. Liu, J. Zhu, et al., “Engineered Probiotics With Sustained Release of Interleukin-2 for the Treatment of Inflammatory Bowel Disease After Oral Delivery,” Biomaterials309 (2024): 122584, https://doi.org/10.1016/j.biomaterials.2024.122584.

[26] J. Zhou, M. Li, Q. Chen, et al., “Programmable Probiotics Modulate Inflammation and Gut Microbiota for Inflammatory Bowel Disease Treatment After Effective Oral Delivery,” Nature Communications13 (2022): 3432, https://doi.org/10.1038/s41467-022-31171-0.

[27] M. Oladejo, Y. Paterson, and L. M. Wood, “Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies,” Frontiers in Immunology12 (2021): 642316, https://doi.org/10.3389/fimmu.2021.642316.

[28] P. C. Maciag, S. Radulovic, and J. Rothman, “The First Clinical Use of a Live-Attenuated Listeria Monocytogenes Vaccine: A Phase I Safety Study of Lm-LLO-E7 in Patients With Advanced Carcinoma of the Cervix,” Vaccine27 (2009): 3975-3983, https://doi.org/10.1016/j.vaccine.2009.04.041.

[29] C. Smith, E. Smith, A. Rydlova, et al., “Protocol for the Challenge Non-Typhoidal Salmonella (CHANTS) Study: A First-In-Human, In-Patient, Double-Blind, Randomised, Safety and Dose-Escalation Controlled Human Infection Model in the UK,” Bmj Open14 (2024): e076477, https://doi.org/10.1136/bmjopen-2023-076477.

[30] J. P. Lynch, L. Goers, and C. F. Lesser, “Emerging Strategies for Engineering Escherichia coli Nissle 1917-based Therapeutics,” Trends in Pharmacological Sciences43 (2022): 772-786, https://doi.org/10.1016/j.tips.2022.02.002.

[31] C. R. Gurbatri, G. A. Radford, L. Vrbanac, et al., “Engineering Tumor-Colonizing E. coli Nissle 1917 for Detection and Treatment of Colorectal Neoplasia,” Nature Communications15 (2024): 646, https://doi.org/10.1038/s41467-024-44776-4.

[32] S. Heilbronner, B. Krismer, H. Brötz-Oesterhelt, and A. Peschel, “The Microbiome-Shaping Roles of Bacteriocins,” Nature Reviews Microbiology19 (2021): 726-739, https://doi.org/10.1038/s41579-021-00569-w.

[33] M. Cui, T. Sun, S. Li, et al., “NIR Light-Responsive Bacteria With Live Bio-Glue Coatings for Precise Colonization in the Gut,” Cell Reports36 (2021): 109690, https://doi.org/10.1016/j.celrep.2021.109690.

[34] C. B. Kurtz, Y. A. Millet, M. K. Puurunen, et al., “An Engineered E. coli Nissle Improves Hyperammonemia and Survival in Mice and Shows Dose-Dependent Exposure in Healthy Humans,” Science Translational Medicine11 (2019): eaau7975, https://doi.org/10.1126/scitranslmed.aau7975.

[35] V. M. Isabella, B. N. Ha, M. J. Castillo, et al., “Development of a Synthetic Live Bacterial Therapeutic for the Human Metabolic Disease Phenylketonuria,” Nature Biotechnology36 (2018): 857-864, https://doi.org/10.1038/nbt.4222.

[36] T. Harimoto, J. Hahn, Y.-Y. Chen, et al., “A Programmable Encapsulation System Improves Delivery of Therapeutic Bacteria in Mice,” Nature Biotechnology40 (2022): 1259-1269, https://doi.org/10.1038/s41587-022-01244-y.

[37] Y. Zhang, Y. Zhang, L. Xia, et al., “Escherichia coli Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors Through Expression of Azurin Protein,” Applied and Environmental Microbiology78 (2012): 7603-7610, https://doi.org/10.1128/AEM.01390-12.

[38] S. Carpenter and L. A. J. O'Neill, “From Periphery to Center Stage: 50 Years of Advancements in Innate Immunity,” Cell187 (2024): 2030-2051, https://doi.org/10.1016/j.cell.2024.03.036.

[39] A. M. Hajjar, R. K. Ernst, J. H. Tsai, C. B. Wilson, and S. I. Miller, “Human Toll-Like Receptor 4 Recognizes Host-Specific LPS Modifications,” Nature Immunology3 (2002): 354-359, https://doi.org/10.1038/ni777.

[40] A. Decout, J. D. Katz, S. Venkatraman, and A. Ablasser, “The cGAS–STING Pathway as a Therapeutic Target in Inflammatory Diseases,” Nature Reviews Immunology21 (2021): 548-569, https://doi.org/10.1038/s41577-021-00524-z.

[41] J. H. Fritz, R. L. Ferrero, D. J. Philpott, and S. E. Girardin, “Nod-Like Proteins in Immunity, Inflammation and Disease,” Nature Immunology7 (2006): 1250-1257, https://doi.org/10.1038/ni1412.

[42] K. M. Hartung and E. M. Sletten, “Bioorthogonal Chemistry: Bridging Chemistry, Biology, and Medicine,” Chemistry (Weinheim An Der Bergstrasse, Germany)9 (2023): 2095-2109, https://doi.org/10.1016/j.chempr.2023.05.016.

[43] N. K. Devaraj, “The Future of Bioorthogonal Chemistry,” ACS Central Science4 (2018): 952-959, https://doi.org/10.1021/acscentsci.8b00251.

[44] N. Gong, X. Han, L. Xue, et al., “In Situ PEGylation of CAR T Cells Alleviates Cytokine Release Syndrome and Neurotoxicity,” Nature Materials (2023): 1571-1580, https://doi.org/10.1038/s41563-023-01646-6.

[45] N. G. Kotla, S. R. Bonam, S. Rasala, et al., “Recent Advances and Prospects of Hyaluronan as a Multifunctional Therapeutic System,” Journal of Controlled Release336 (2021): 598-620, https://doi.org/10.1016/j.jconrel.2021.07.002.

[46] F. Chen, P. Le, K. Lai, G. M. Fernandes-Cunha, and D. Myung, “Simultaneous Interpenetrating Polymer Network of Collagen and Hyaluronic Acid as an In Situ-Forming Corneal Defect Filler,” Chemistry of Materials32 (2020): 5208-5216, https://doi.org/10.1021/acs.chemmater.0c01307.

[47] X. Li, J. F. Lovell, J. Yoon, and X. Chen, “Clinical Development and Potential of Photothermal and Photodynamic Therapies for Cancer,” Nature Reviews Clinical Oncology17 (2020): 657-674, https://doi.org/10.1038/s41571-020-0410-2.

[48] H. Shi and P. J. Sadler, “How Promising Is Phototherapy for Cancer?” British Journal of Cancer123 (2020): 871-873, https://doi.org/10.1038/s41416-020-0926-3.

[49] O. Shatursky, A. P. Heuck, L. A. Shepard, et al., “The Mechanism of Membrane Insertion for a Cholesterol-Dependent Cytolysin,” Cell99 (1999): 293-299, https://doi.org/10.1016/S0092-8674(00)81660-8.

[50] Y.-J. Wang, L. Li, J. Yu, et al., “Imaging of Escherichia coli K5 and Glycosaminoglycan Precursors via Targeted Metabolic Labeling of Capsular Polysaccharides in Bacteria,” Science Advances9 (2023): eade4770, https://doi.org/10.1126/sciadv.ade4770.

[51] P. H. Weigel, “Hyaluronan Synthase: The Mechanism of Initiation at the Reducing End and a Pendulum Model for Polysaccharide Translocation to the Cell Exterior,” International Journal of Cell Biology2015 (2015): 1-15, https://doi.org/10.1155/2015/367579.

[52] L. Zhang, H. Huang, H. Wang, J. Chen, G. Du, and Z. Kang, “Rapid Evolution of Hyaluronan Synthase to Improve Hyaluronan Production and Molecular Mass in Bacillus Subtilis,” Biotechnology Letters38 (2016): 2103-2108, https://doi.org/10.1007/s10529-016-2193-1.

[53] L. Liu, Y. Liu, J. Li, G. Du, and J. Chen, “Microbial Production of Hyaluronic Acid: Current state, Challenges, and Perspectives,” Microbial Cell Factories10 (2011): 99, https://doi.org/10.1186/1475-2859-10-99.

[54] F.-X. Yin, F. X. Yin, F. S. Wang, F. Wang, J.-Z. Sheng, and J. Z. Sheng, “Uncovering the Catalytic Direction of Chondroitin AC Exolyase,” Journal of Biological Chemistry291 (2016): 4399-4406, https://doi.org/10.1074/jbc.C115.708396.

[55] C. T. Moody, S. Palvai, and Y. Brudno, “Click Cross-linking Improves Retention and Targeting of Refillable alginate Depots,” Acta Biomaterialia112 (2020): 112-121, https://doi.org/10.1016/j.actbio.2020.05.033.

[56] Z. Zhang, F. Vogelbacher, Y. Song, Y. Tian, and M. Li, “Bio-Inspired Optical Structures for Enhancing Luminescence,” Exploration3 (2023): 20220052, https://doi.org/10.1002/EXP.20220052.

[57] C. R. Gurbatri, I. Lia, R. Vincent, et al., “Engineered Probiotics for Local Tumor Delivery of Checkpoint Blockade Nanobodies,” Science Translational Medicine12 (2020): eaax0876, https://doi.org/10.1126/scitranslmed.aax0876.

[58] T. Chien, T. Harimoto, B. Kepecs, et al., “Enhancing the Tropism of Bacteria via Genetically Programmed Biosensors,” Nature Biomedical Engineering6 (2022): 94-104, https://doi.org/10.1038/s41551-021-00772-3.

[59] M. H. Abedi, M. S. Yao, D. R. Mittelstein, et al., “Ultrasound-Controllable Engineered Bacteria for Cancer Immunotherapy,” Nature Communications13 (2022): 1585, https://doi.org/10.1038/s41467-022-29065-2.

[60] Y. C. Kim, A. W. Tarr, and C. N. Penfold, “Colicin Import Into E. coli Cells: A Model System for Insights Into the Import Mechanisms of Bacteriocins,” Biochimica Et Biophysica Acta (BBA)—Molecular Cell Research1843 (2014): 1717-1731, https://doi.org/10.1016/j.bbamcr.2014.04.010.

[61] F. Vanderwal, J. Luirink, and B. Oudega, “Bacteriocin Release Proteins: Mode of Action, Structure, and Biotechnological Application,” FEMS Microbiology Reviews17 (1995): 381-399, https://doi.org/10.1016/0168-6445(95)00022-4.

[62] N. Dekker, J. Tommassen, and H. M. Verheij, “Bacteriocin Release Protein Triggers Dimerization of Outer Membrane Phospholipase A In Vivo,” Journal of Bacteriology181 (1999): 3281-3283, https://doi.org/10.1128/JB.181.10.3281-3283.1999.

[63] D. G. Millar, R. R. Ramjiawan, K. Kawaguchi, et al., “Antibody-Mediated Delivery of Viral Epitopes to Tumors Harnesses CMV-Specific T Cells for Cancer Therapy,” Nature Biotechnology38 (2020): 420-425, https://doi.org/10.1038/s41587-019-0404-8.

[64] S. Suh, A. Jo, M. A. Traore, et al., “Nanoscale Bacteria-Enabled Autonomous Drug Delivery System (NanoBEADS) Enhances Intratumoral Transport of Nanomedicine,” Advanced Science6 (2019): 1801309, https://doi.org/10.1002/advs.201801309.

[65] A. T. St Jean, C. A. Swofford, J. T. Panteli, Z. J. Brentzel, and N. S. Forbes, “Bacterial Delivery of Staphylococcus aureus α-Hemolysin Causes Regression and Necrosis in Murine Tumors,” Molecular Therapy22 (2014): 1266-1274, https://doi.org/10.1038/mt.2014.36.

[66] J. L. Galeano Niño, H. Wu, K. D. Lacourse, et al., “INVADEseq to Identify Cell-Adherent or Invasive Bacteria and the Associated Host Transcriptome at Single-Cell-Level Resolution,” Nature Protocols18 (2023): 3355-3389, https://doi.org/10.1038/s41596-023-00888-7.

[67] A. Fu, B. Yao, T. Dong, et al., “Tumor-Resident Intracellular Microbiota Promotes Metastatic Colonization in Breast Cancer,” Cell185 (2022): 1356-1372.e26, https://doi.org/10.1016/j.cell.2022.02.027.

[68] P. Meiser, M. A. Knolle, A. Hirschberger, et al., “A Distinct Stimulatory cDC1 Subpopulation Amplifies CD8+ T Cell Responses in Tumors for Protective Anti-Cancer Immunity,” Cancer Cell41 (2023): 1498-1515.e10, https://doi.org/10.1016/j.ccell.2023.06.008.

[69] K. Adu-Berchie, Y. Liu, D. K. Y. Zhang, et al., “Generation of Functionally Distinct T-cell Populations by Altering the Viscoelasticity of Their Extracellular Matrix,” Nature Biomedical Engineering7 (2023): 1374-1391, https://doi.org/10.1038/s41551-023-01052-y.

[70] R. C. Lynn, E. W. Weber, E. Sotillo, et al., “c-Jun Overexpression in CAR T Cells Induces Exhaustion Resistance,” Nature576 (2019): 293-300, https://doi.org/10.1038/s41586-019-1805-z.

[71] P. Rodríguez-Silvestre, M. Laub, P. A. Krawczyk, et al., “Perforin-2 Is a Pore-Forming Effector of Endocytic Escape in Cross-Presenting Dendritic Cells,” Science380 (2023): 1258-1265, https://doi.org/10.1126/science.adg8802.

[72] M. Wichroski, J. Benci, S.-Q. Liu, et al., “DGKα/ζ Inhibitors Combine With PD-1 Checkpoint Therapy to Promote T Cell–mediated Antitumor Immunity,” Science Translational Medicine15 (2023): eadh1892, https://doi.org/10.1126/scitranslmed.adh1892.

[73] W. Wang, H. Xu, Q. Ye, et al., “Systemic Immune Responses to Irradiated Tumours via the Transport of Antigens to the Tumour Periphery by Injected Flagellate Bacteria,” Nature Biomedical Engineering6 (2022): 44-53, https://doi.org/10.1038/s41551-021-00834-6.

[74] E. Kugelberg, “TLR Agonists Trigger Rapid Metabolic Changes,” Nature Reviews Immunology14 (2014): 209-209, https://doi.org/10.1038/nri3652.

[75] Q. Chen, L. Sun, and Z. J. Chen, “Regulation and Function of the cGAS–STING Pathway of Cytosolic DNA Sensing,” Nature Immunology17 (2016): 1142-1149, https://doi.org/10.1038/ni.3558.

[76] W. Strober, P. J. Murray, A. Kitani, and T. Watanabe, “Signalling Pathways and Molecular Interactions of NOD1 and NOD2,” Nature Reviews Immunology6 (2006): 9-20, https://doi.org/10.1038/nri1747.

[77] Y. Xu, A. Zhou, W. Chen, et al., “An Integrative Bioorthogonal Nanoengineering Strategy for Dynamically Constructing Heterogenous Tumor Spheroids,” Advanced Materials35 (2023): 2304172, https://doi.org/10.1002/adma.202304172.

[78] C. Gao and K. J. Edgar, “Efficient Synthesis of Glycosaminoglycan Analogs,” Biomacromolecules20 (2019): 608-617, https://doi.org/10.1021/acs.biomac.8b01150.

[79] B. L. Hartwell, C. J. Pickens, M. Leon, and C. Berkland, “Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy Against Experimental Autoimmune Encephalomyelitis,” Biomacromolecules18 (2017): 1893-1907, https://doi.org/10.1021/acs.biomac.7b00335.

[80] M. A. Leon, R. Firdessa-Fite, J. K. Ruffalo, et al., “Soluble Antigen Arrays Displaying Mimotopes Direct the Response of Diabetogenic T Cells,” ACS Chemical Biology14 (2019): 1436-1448, https://doi.org/10.1021/acschembio.9b00090.

[81] P. Meier, A. J. Legrand, D. Adam, and J. Silke, “Immunogenic Cell Death in Cancer: Targeting Necroptosis to Induce Antitumour Immunity,” Nature Reviews Cancer (2024): 299-315, https://doi.org/10.1038/s41568-024-00674-x.

[82] A. Melcher, K. Harrington, and R. Vile, “Oncolytic Virotherapy as Immunotherapy,” Science374 (2021): 1325-1326, https://doi.org/10.1126/science.abk3436.

[83] J. L. Galeano Niño, H. Wu, K. D. Lacourse, et al., “Effect of the Intratumoral Microbiota on Spatial and Cellular Heterogeneity in Cancer,” Nature611 (2022): 810-817, https://doi.org/10.1038/s41586-022-05435-0.

[84] U. Sahin and Ö. Türeci, “Personalized Vaccines for Cancer Immunotherapy,” Science359 (2018): 1355-1360, https://doi.org/10.1126/science.aar7112.

[85] M. Müller, F. Huber, M. Arnaud, et al., “Machine Learning Methods and Harmonized Datasets Improve Immunogenic Neoantigen Prediction,” Immunity56 (2023): 2650-2663.e2656.

[86] P. D. Katsikis, K. J. Ishii, and C. Schliehe, “Challenges in Developing Personalized Neoantigen Cancer Vaccines,” Nature Reviews Immunology24 (2024): 213-227, https://doi.org/10.1038/s41577-023-00937-y.

[87] V. Raman, C. P. Deshpande, S. Khanduja, L. M. Howell, N. Van Dessel, and N. S. Forbes, “Build-a-Bug Workshop: Using Microbial-Host Interactions and Synthetic Biology Tools to Create Cancer Therapies,” Cell Host & Microbe31 (2023): 1574-1592, https://doi.org/10.1016/j.chom.2023.09.006.

[88] T. Danino, A. Prindle, G. A. Kwong, et al., “Programmable Probiotics for Detection of Cancer in Urine,” Science Translational Medicine7 (2015): 289ra284, https://doi.org/10.1126/scitranslmed.aaa3519.

[89] D. T. Riglar and P. A. Silver, “Engineering Bacteria for Diagnostic and Therapeutic Applications,” Nature Reviews Microbiology16 (2018): 214-225, https://doi.org/10.1038/nrmicro.2017.172.

[90] C. K. Schmidt, M. Medina-Sánchez, R. J. Edmondson, and O. G. Schmidt, “Engineering Microrobots for Targeted Cancer Therapies From a Medical Perspective,” Nature Communications11 (2020): 5618, https://doi.org/10.1038/s41467-020-19322-7.

[91] S. J. Blake, Y. Wolf, B. Boursi, and D. J. Lynn, “Role of the Microbiota in Response to and Recovery From Cancer Therapy,” Nature Reviews Immunology24 (2023): 308-328.

[92] R. Salomir, F. C. Vimeux, J. A. de Zwart, N. Grenier, and C. T. W. Moonen, “Hyperthermia by MR-Guided Focused Ultrasound: Accurate Temperature Control Based on Fast MRI and a Physical Model of Local Energy Deposition and Heat Conduction,” Magnetic Resonance in Medicine43 (2000): 342-347, https://doi.org/10.1002/(SICI)1522-2594(200003)43:3%3c342::AID-MRM4%3e3.0.CO;2-6.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.